Mounjaro and Pregnancy Risk: What the Evidence Says

Step 1: Understand why Mounjaro is not suitable during pregnancy

The short answer is that nobody knows what tirzepatide does to a developing baby, and that uncertainty is reason enough to avoid it. The clinical trials that established Mounjaro's safety and effectiveness excluded pregnant women entirely, so there are no human data to draw on. What does exist comes from animal studies, and those studies found developmental problems at doses that are relevant to the amounts used in people. The full risk profile of Mounjaro is still being built; it carries a Black Triangle (▼) status from the MHRA, meaning it is subject to additional monitoring precisely because it is relatively new in widespread use.

Slowed gastric emptying (one of tirzepatide's main mechanisms) could in theory affect how nutrients and other medicines are absorbed during a pregnancy. That is speculative, but it adds to the case for caution. If you want a thorough breakdown of whether tirzepatide is safe during pregnancy, including what the animal data actually showed and why regulators take it seriously, that page covers the evidence in full. That guidance exists because the precautionary principle applies most forcefully where the person at risk cannot consent.

This is not a situation where clinical judgement leaves much room for manoeuvre. The guidance from the NHS tirzepatide medicines page is unambiguous: tirzepatide should not be used in pregnancy.

Step 2: Know what to do if you become pregnant while taking Mounjaro

Stop the medicine and contact your GP or midwife the same day. You do not need to wait for your next scheduled prescriber review, call now. Your maternity team will want to know what dose you were taking and when your last injection was.

The next practical step is straightforward and takes under a minute: check the date on your last pen to confirm exactly when you last injected, then note it down before you make the call. Prescribers find this genuinely useful when assessing timing and planning any monitoring.

The washout period for tirzepatide (how long it stays active in the body) is relevant here. Based on its pharmacokinetics, the medicine can remain measurable for several weeks after the last dose. Your GP and maternity team will factor this in. Do not restart Mounjaro after delivery without a fresh clinical assessment; weight management options in the postnatal period, including while breastfeeding, need to be discussed with a prescriber who knows your full picture. You can read more about whether Mounjaro is safe for pregnant women in detail, including what limited case reports show.

Step 3: Sort contraception before you start treatment

This step belongs at the beginning of any Mounjaro treatment plan for women of childbearing age, but it is worth revisiting clearly here. The MHRA advises using reliable contraception while on tirzepatide and for a period afterwards if you intend to conceive. NHS England's weight management guidance specifically flags that women using oral contraceptive pills should add a non-oral method (such as condoms) for the first four weeks of Mounjaro treatment and for four weeks after every dose increase. The reason is absorption: tirzepatide slows gastric emptying, which can reduce how reliably the pill is absorbed from the gut.

There is no equivalent evidence that semaglutide (Wegovy) causes the same reduction in pill effectiveness, but the precautionary advice for tirzepatide is clear. Patches, implants, injections and hormonal coils are all absorbed differently and are not affected in the same way. If you are unsure which method you are using or whether it is affected, your GP or our prescribers can advise, and it is worth sorting this before your first pen, not after. Our guide to Mounjaro's side effects covers other areas where the medicine can interact with how your body processes things.

Step 4: Plan the path back to weight management after pregnancy

Stopping Mounjaro for pregnancy does not close the door on future treatment. After delivery and once breastfeeding has ended, weight management medicines can be reconsidered, subject to a full clinical review. A prescriber will look at your current weight, any conditions that have changed during pregnancy, your feeding plans and your overall health before recommending anything.

Breastfeeding is an important consideration in its own right. It is not currently known whether tirzepatide passes into breast milk in meaningful amounts, and on that basis it is not recommended while breastfeeding. This mirrors the approach taken with most prescription weight management medicines. If you want to understand the full picture before starting or stopping treatment, our page on whether Mounjaro is safe in pregnancy covers the key questions and clinical reasoning in one place. The detailed page on Mounjaro side effects in the context of pregnancy explains the biological reasoning in more depth.

When the time is right and breastfeeding has ended, our prescribers carry out a same-day clinical review of every new consultation, a real prescriber reads your answers, not automated software. You can explore the full range of weight management treatments we offer when you are at that stage, and our clinical team is available to answer questions along the way. For anyone weighing up the options more broadly, the weight loss treatment overview sets out the landscape clearly.